Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,894 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,160 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02223078 | Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.(CC4) | completed | Phase 2 | — | Cancer Advances Inc.INDUSTRY | 1 | Jun 20, 2017 | clinicaltrials |
| NCT02246049 | A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC(QUATTRO) | completed | Phase 2 | 69 | EPS CorporationOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib(UAB0040) | completed | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT01383707 | A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer | completed | Phase 2 | 77 | Hoffmann-La RocheINDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00381862 | Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00636610 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | completed | Phase 2 | 199 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00468910 | Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer | completed | Phase 2 | 79 | National Cancer Institute (NCI)NIH | 1 | May 31, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT01418222 | FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 194 | Genentech, Inc.INDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT02219893 | Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial(ImmunoPeCa) | completed | Phase 1 / Phase 2 | 15 | Oslo University HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00842257 | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT03146377 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 32 | The University of Hong KongOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01051167 | Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer(CEBIFOX) | completed | Phase 2 | 59 | Martin Schuler, Prof. Dr. med.OTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT00004005 | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin | completed | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01722162 | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | completed | Phase 2 | 47 | Washington University School of MedicineOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00828984 | Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00030563 | Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver | completed | Phase 2 | — | University of WashingtonOTHER | 2 | Apr 17, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT01273051 | Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer(CARTS) | completed | Phase 2 | 55 | Radboud University Medical CenterOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT00002842 | Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer | completed | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01292356 | Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response | completed | Phase 2 | 28 | Poitiers University HospitalOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01047293 | RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 47 | University of UtahOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01523431 | Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | completed | Phase 2 / Phase 3 | 583 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00153816 | Vitamin D/Calcium Polyp Prevention Study | completed | Phase 2 / Phase 3 | 2,813 | Dartmouth-Hitchcock Medical CenterOTHER | 2 | Mar 15, 2017 | clinicaltrials |
| NCT01289821 | First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib | completed | Phase 2 | 54 | BayerINDUSTRY | 7 | Mar 15, 2017 | clinicaltrials |
| NCT01060007 | Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer | completed | Phase 2 | 80 | Washington University School of MedicineOTHER | 1 | Mar 8, 2017 | clinicaltrials |
| NCT01150877 | High Dose Vitamin D Study | completed | Phase 1 / Phase 2 | 40 | University of British ColumbiaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02526134 | Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum(FIDUCOR) | completed | Phase 2 | 29 | Institut Paoli-CalmettesOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01802684 | OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer(VELVET) | completed | Phase 2 | 49 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00303875 | Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight | completed | Phase 2 | 641 | Duke UniversityOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00335504 | Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia | completed | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01749956 | 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer | completed | Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00203411 | Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 45 | Translational Oncology Research InternationalOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00056030 | Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01507103 | Tecemotide (L-BLP25) in Rectal Cancer(SPRINT) | completed | Phase 2 | 124 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jan 13, 2017 | clinicaltrials |
| NCT02694718 | A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02236884 | The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer | completed | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00016952 | Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 19 | Alliance for Clinical Trials in OncologyOTHER | 2 | Dec 7, 2016 | clinicaltrials |
| NCT00080951 | Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 14 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02077777 | Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway. | completed | Phase 2 | 21 | SOFAR S.p.A.INDUSTRY | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01450319 | Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype(MUTEX) | completed | Phase 2 | 73 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 28, 2016 | clinicaltrials |
| NCT01549535 | Polyp Detection With The Peerscope System™ | completed | Phase 2 | 197 | PeerMedical Ltd.INDUSTRY | 3 | Nov 25, 2016 | clinicaltrials |
| NCT00362102 | A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | completed | Phase 2 | 38 | Eli Lilly and CompanyINDUSTRY | 0 | Nov 22, 2016 | clinicaltrials |
| NCT00912743 | Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | completed | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Nov 9, 2016 | clinicaltrials |
| NCT00527111 | Pre-op Rectal ChemoRad +/- Cetuximab | completed | Phase 2 | 139 | US Oncology ResearchINDUSTRY | 1 | Nov 3, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jun 26, 2017source: clinicaltrials